Lipids as key players in Alzheimer disease - Alterations in metabolism and genetics

Current Alzheimer Research

Volumn 5, Issue 1, 2008, Pages 4-14

  Sagin, Ferhan Girgin ^a   Sozmen, Eser Yildirim ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

24 OH cholesterol; ABCA1; ACAT; Alzheimer disease; Amyloid precursor protein; ApoE; Cholesterol; Membrane

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; OXYSTEROL;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; CHOLESTEROL METABOLISM; GENETIC ASSOCIATION; HUMAN; MOLECULAR GENETICS; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHOLESTEROL; HUMANS; LIPID METABOLISM; MEMBRANE LIPIDS; NERVE TISSUE PROTEINS;

EID: 42149166663     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783884648     Document Type: Review

References (107)

1. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, et al. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun 181 (1): 265-271(1991).
2. V717F transgenic mouse model of Alzheimer's Disease. Proc Natl Acad Sci USA 96: 15233-15238 (1999).
3. Björkhem I and Meaney S. Brain Cholesterol: Long Secret Life Behind a Barrier Arterioscler Thromb Vasc Biol 24: 806-815 (2004).
4. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 139: 577-583 (2000).
5. Bodovitz S and Klein WL. Cholesterol Modulates α-Secretase Cleavage of Amyloid Precursor Protein. J Biol Chem 271 (8): 4436-4440 (1996).
6. Borroni B, Archetti S, Agosti C, Akkawi N, Brambilla C, Caimi L, et al. Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzhemier Disease: from risk factors to disease modulators. Neurobiol Aging 25: 747-751 (2004).
7. Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47 (1986).
8. Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem279 (33): 34674-34681 (2004).
9. Chalmers KA, Culpan D, Kehoe PG, Wilcock GK, Hughes A, Love S. APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. Neuroreport 15: 95-98 (2004).
10. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of Aβ (1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272: 22987-22990 (1997).
11. Chung H, Roberts CT, Greenberg S, Rebeck GW, Christie R, Wallace R, et al. Lack of association of trinucleotide repeat polymorphisms in very-low-density lipoprotein receptor gene with Alzheimer's disease. Ann Neurol 39 (6): 800-803 (1996).
12. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 13;261(5123):921-923 (1993).
13. Corsini A. Fluvastatin: effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther 5:161-175 (2000).
14. Czyzewski K, Lalowski MM, Pfeffer A, Barcikowska M. Lipid metabolism parameters in patients with Alzheimer's disease and their first degree relatives. Acta Neurobiol Exp 61: 21-26 (2001).
15. Davignon J and Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10: 543-559 (1999).
16. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 138: 877-889 (1997).
17. Desai P, DeKosky ST, Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzhemier's disease. Neurosci Lett 328 (1): 9-12 (2002).
18. Dietschy JM, Kita T, Suckling KE, Goldstein JL, Brown MS. Cholesterol synthesis in vivo and in vitro in the WHHL rabbit, an animal with defective low density lipoprotein receptors. J Lipid Res 24: 469-480 (1983).
19. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 12:105-112 (2001).
20. Edidin M. The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct 32: 257-283 (2003).
21. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-123 (2003).
22. Fan QW, Wei Y, Senda T, Yanagisawa K and Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 76: 391-400 (2001).
23. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta - amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA 98 (10): 5856-5861 (2001).
24. Fernandes MA. Effects of apolipoprotein E genotype on blood lipid composition and membrane platelet fluidity in Alzheimer Disease. Biochym Biophys Acta 1454: 89-96 (1999).
25. Friedman G, Froom P, Sazbon L, Grinblatt I, Shochina M, Tsenter J, et al. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 52:244-8 (1999).
26. Gong JS, Sawamura N, Zou K, Sakai J, Yanagisawa K and Michikawa M. Amyloid-protein affects cholesterol metabolism in cultured neurons: Implications for pivotal role of cholesterol in the amyloid cascade. J Neurosci Res 70: 438- 446 (2002).
27. Goodrum JF. Cholesterol from degenerating nerve myelin becomes associated with lipoproteins containing apolipoprotein Eur J Neurochem 56:2082-2086 (1991).
28. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 100 (19): 10966-10971 (2003).
29. Herz J, Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's Disease. Nat Rev Neurosci 1:51-58 (2000).
30. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126(1): 88-94 (1994).
31. Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci USA 98 (15): 8838-8843 (2001).
32. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44 (2): 227-238 (2004).
33. Johannsson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, et al. Variants of CYP46A1 may interact with age and ApoE to influence CSF Aβ42 levels in Alzheimer's disease. Hum Genet 114: 581-587 (2004).
34. Juhasz A, Palotas A, Janka Z, Rimanoczy A, Palotas M, Bodi N, et al. ApoE -491A/T promoter polymorphism is not an independent risk factor, but associated with the epsilon4 allele in Hungarian Alzheimer's dementia population. Neurochem Res 30 (5): 591-596 (2005).
35. Kabara A, Payet N, Cottel D, Frigard B, Amouyel P, Lambert JC. Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population. Neurosci Lett 363: 139-143 (2004).
36. Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol- dependent formation of GM1 ganglioside bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276: 24985-24990 (2001).
37. Katzov H, Chalmers K, Palmgren J, Andreasen N, Johannson B, Cairns NJ, et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat 23 (4): 358-367 (2004).
38. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23 (12): 1663-1667 (2003).
39. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E e4 allele, elevated midlife total cholesterol and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer's disease. Ann Intern Med 137: 149-155 (2002).
40. Knebl J. Plasma lipids and cholesterol esterification in Alzheimer's Disease. Mech Ageing Dev 73: 69-77 (1994).
41. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 98: 5815-5820 (2001).
42. Kolsch H, Lütjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, et al. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 7(8): 899-902 (2002).
43. LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 70: 2070-2081 (1998).
44. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P, Chartier-Harlin MC. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet 7 (3): 533-540 (1998).
45. Lambert JC, Brousseau1 T, Defosse1 V, Evans A, Arveiler D, Ruidavets JB, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations - the ECTIM Study. Hum Mol Genet 9 (1): 57-61 (2000).
46. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT and Kosik KS. A detergent- insoluble membrane compartment contains Aβ in vivo. Nat Med 4: 730-734 (1998).
47. Locatelli S, Lütjohann D, Schmidt HHJ, Otto C, Beisiegel U, Bergmann K. Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients With Hypercholesterolemia: Evidence That Simvastatin Affects Cholesterol Metabolism in the Human Brain. Arch Neurol 59:213-216 (2002).
48. Lund EG, Guileyardo JM and Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96: 7238-7243 (1999).
49. Lundbaek JA, Birn P, Girshman J, Hansen AJ, Andersen OS. Membrane stiffness and Channel function. Biochem 35: 3825-3830 (1996).
50. Lütjohann D, Papassotiropoulos A, Björkhemd I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41: 195-198 (2000).
51. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, et al . Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93: 9799-9804 (1996).
52. Mace S, Cousin E, Ricard S, Genin E, Spanakis E, Lafargue-Soubigou C, et al. ABCA2 is a strong genetic risk factor for earlyonset Alzhemier's disease. Neurobiol Dis 18: 119-125 (2005).
53. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630 (1988).
54. Matsuzaki K and Horikiri C. Interactions of amyloid β-peptide (1-40) with ganglioside containing membranes. Biochemistry 38: 4137-4142 (1999).
55. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357 (2001).
56. Michikawa M, Fan QW, Isobe I and Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74 (3): 1008-1016 (2000).
57. Michikawa M, Gong JS, Fan QW, Sawamura N and Yanagisawa K. A novel action of Alzheimer's amyloid b-protein (Ab): oligomeric Ab promotes lipid release. J Neurosci 21(18): 7226-7235 (2001).
58. Michikawa M. The Role of Cholesterol in Pathogenesis of Alzheimer's Disease. Mol Neurobiol 27: 1-12 (2003).
59. Michikawa M. Neurodegenerative Disorders and Cholesterol. Curr Alzheim Res 1(4): 271-275 (2004).
60. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. Elevated total cholesterol levels in late-life associated with a reduced risk of dementia. Neurology 64: 1689-1695 (2005).
61. Mills J, Reiner PB. Regulation of Amyloid Precursor Protein Cleavage. J Neurochem 72: 443-460 (1999).
62. Mitter D, Hinz B, Reisinger C, Hollmann S, Yelamanchili SV, Treiber-Held S, et al. The synaptophysin/synaptobrevin interaction critically depends on the cholesterol content. J Neurochem 84: 35-42 (2003).
63. Mori T. Cholesterol accumulates in senile plaques of Alzheimer Disease patients and in transgenic APP (SW) mice. J Neuropathol Exp Neurol 60: 778-785 (2001).
64. Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J, et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheim Dis Assoc Disords 12: 198-203 (1998).
65. Ohkubo T, Shibata N, Ohnuma T, Higashi S, Usui C, Ueki A, et al. No genetic association between ATP binding cassette proteins and Japanese sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 20: 95-98 (2005).
66. Okuizumi K, Onodera O, Seki K, Tanaka H, Namba Y, Ikeda K, et al. Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Ann Neurol 40 (2): 251-254 (1996).
67. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, et al. Increased brain β-amyloid load, phosphorylated tau and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60: 29-35 (2003).
68. Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25: 72-78 (2003).
69. Poirier J. Apolipoprotein E and Alzheimer's Disease A Role in Amyloid Catabolism. Ann NY Acad Sci 924: 81-85 (2000).
70. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 26 (3): 355-61 (2005).
71. Posse de Chaves E, Rusiñol A, Campenot RB, Vance DE, Vance JE. Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J Biol Chem 272: 30766-30773 (1997).
72. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT. Acyl-coenzyme A: cholesterol acyl transferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 3: 905-912 (2001).
73. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's Disease: the cholesterol connection Nature Neuroscience 6 (4): 345-351 (2003).
74. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, et al. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322: 893-898 (1997).
75. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331 (2000).
76. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899 (2001).
77. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61: 705-714 (2004).
78. Riemenschneider M, Mahmoodzadeh S, Eisele T, Klopp N, Schwarz S, Wagenpfeil S, et al. Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromsome 10 and Alzheimer's disease. Neurobiol Aging 25(10): 1305-1308 (2004).
79. Romas SN, Tang MX, Berglund L, Mayeux R. APOE genotype, plasma lipids, lipoproteins and AD in community elderly. Neurology 53: 517-521 (1999).
80. Roth GS, Joseph JA, Mason RP. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci 18: 203-206 (1995).
81. Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, et al. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22: 1679-1689 (2002).
82. Scacchi R, Gambina G, Martini MC, Ruggeri M, Ferrari G, Sivestri M, et al. Polymorphisms of the apolipoprotein E gene regulatory region and of the LDL receptor gene in Late-onset Alzheimer's disease in relation to the plasma lipidic pattern. Dement Geriatr Cogn Disord 12: 63-68 (2001).
83. Schubert D, Cole G, Saitoh T, Oltersdorf T. Amyloid beta protein precursor is a mitogen. Biochem Biophys Res Commun 162(1): 83-88 (1989).
84. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 6: 487-498 (1991).
85. Shibata N, Kawarai T, Lee JL, Lee HS, Shibata E, Sato C, et al. Assocaition studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease. Neurosci Lett 391: 142-146. (2006).
86. Sidera C, Parson R, Austen D. Proteolytic cascade in the amyloidogenesis of AD. Biochem Soc Trans 32: 33-36 (2004).
87. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95: 6460-6464 (1998).
88. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52(3): 346-350 (2002).
89. Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126: 88-94 (1994).
90. Sparks DL. Intraneuronal beta-amyloid immunoreactivity in the CNS. Neurobiol Aging 17: 291-9 (1996).
91. Sparks DL, Martin TA, Gross DR, Hunsaker JC. Link between heart disease, cholesterol and Alzheimer's Disease. Microsc Res Tech 50: 287-290 (2000).
92. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 92: 4725-4727 (1995).
93. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 163(9): 1053-7 (2003).
94. Tanaka Y, Yamada K, Zhou CJ, Ban N, Shioda S, Inagaki N. Temporal and spatial profiles of ABCA2-expressing oligodendrocytes in the developing rat brain. J Comp Neurol 455: 353-367 (2003).
95. Thelen KM, Falkai P, Bayer TA, Lutjohann D. Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci Lett. 31;403 (1-2): 15-19 (2006).
96. Vance JE, Hayashi H, Karten B. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 16: 193-212 (2005).
97. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 348: 1079-1082 (1996).
98. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 23 (7): 871-880 (2003).
99. Wang JC, Kwon JM, Shah P, Morris JC, Goate A. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. Neurology 55:1644-1649 (2000).
100. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, et al. Cholesterol- dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 9: 11-23 (2002).
101. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, et al. ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE. J Biol Chem 279 (39): 40987-40993 (2004).
102. Wollmer MA, Streffer JR, Lütjohann D, Tsolaki M, Iakovidou V, Hegi T, Pasch T, Jung HH, von Bergman K, Nitsch RM, Hock C, Papassotiropoulos A. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24: 421-426 (2003).
103. Wollmer MA, Streffer JR, Tsolaki M, Grimaldi LME, Lütjohan D, Thal D, et al. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load and risk for Alzheimer's disease. Mol Psychiatr 8: 635-8 (2003).
104. Wollmer MA, Kapaki E, Hersberger M, Muntwyler J, Brunner F, Tsolaki M, et al. Ethnicity dependent genetic association of ABCA2 with sporadic Alzheimer's disease. Am J Med Genet Part B 141B:1-3 (2006).
105. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10): 1439-43 (2000).
106. Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, et al. APOE, vascular pathology and the AD brain. Neurology; 65(2): 259-265 (2005).
107. Zhao FG, Wang YH, Yang JF, Ma QL, Tang Z, Dong XM, et al. Association between acyl-coenzyme A: cholesterol acyltransferase gene and risk for Alzheimer's disease in Chinese. Neurosci Lett 388 (1): 17-20 (2005).